Filing Flows › Royalty Pharma (RPRX) › Income from financial royalty assets revenue
Royalty Pharma (RPRX) Income from financial royalty assets revenue by quarter
Royalty Pharma's Income from financial royalty assets revenue was $648M in Q3 2026 (third quarter 2026), +2% from Q2 2026. Over the last 7 quarters it ranged from $539M (Q1 2025) to $648M (Q3 2026).
| Quarter | Income from financial royalty assets revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $648M | +2% | +12% |
| Q2 2026 | $638M | +7% | +16% |
| Q1 2026 | $595M | +0.4% | +10% |
| Q4 2025 | $592M | +2% | — |
| Q3 2025 | $579M | +5% | — |
| Q2 2025 | $550M | +2% | — |
| Q1 2025 | $539M | — | — |
Q3 2026 at a glance
Royalty Pharma, Q3 2026: revenue $690M (+13% year over year), operating margin 59.5%, net earnings $145M, operating cash flow $686M. The chart follows the revenue to costs, profit and cash.
Questions
What is Royalty Pharma's Income from financial royalty assets revenue?
Royalty Pharma's Income from financial royalty assets revenue was $648M in Q3 2026 (third quarter 2026), +2% from Q2 2026.
How has Royalty Pharma's Income from financial royalty assets revenue changed?
Over the last 7 quarters it ranged from $539M (Q1 2025) to $648M (Q3 2026).